The pre-existing pharmacological therapy is often integrated with specific medicines, such as anti-anaemic (iron and erythropoietin), treatments for hyperkalaemia and hyperphosphatemia, and anti-parathyroid agents, particularly paricalcitol. This evidence concerns the gene EPO and hyperphosphatemia.